Marketwired

Quotient Limited; Ortho Clinical Diagnostics

Del

Quotient and Ortho Clinical Diagnostics to Present Symposium on Role of Extended Phenotyping in Blood Matching at ISBT

EYSINS, SWITZERLAND and RARITAN, NJ--(Marketwired - Jun 20, 2017) - Quotient Limited (NASDAQ : QTNT ), a commercial-stage diagnostics company, and Ortho Clinical Diagnostics ("Ortho"), a global leader of in vitro diagnostics, today announced they will jointly host a company-sponsored satellite symposium, "Improving Patient Care with Better-matched Blood," on Tuesday, June 20 from 12:00-1:30 p.m., during the 27th Regional Congress of the International Society of Blood Transfusion (ISBT). The ISBT Regional Congress takes place this week in Copenhagen, Denmark.

"The symposium will feature expert perspectives on the limitations of current immunohematology, or blood-matching, practices and potential changes that could dramatically influence future standards of care in transfusion medicine," said Heidi Casaletto, vice president of Transfusion Medicine at Ortho.

"Better matching of donor units to patients is imperative in reducing alloimmunization during transfusions. Alloimmunization poses a threat to patient safety as well as compatibility issues in subsequent transfusions, resulting in a significant economic impact on blood establishments and hospitals," added Paul Cowan, chairman and chief executive officer at Quotient.

Speakers include:

  • Dr. Jonathan Wallis, Newcastle Hospital, UK: "Antibodies and the Haematology Patient"
  • Dr. Jill Storry, Lund University, Sweden: "Strategies to Provide Phenotyped Blood from a Blood Centre"
  • Prof. David Roberts, John Radcliffe Hospital, University of Oxford, UK: "The Future of Blood Group Matching"

During the symposium, which will be moderated by Dr. Geoffrey David Poole (an external consultant for Ortho), speakers will address the role of extended phenotyping to better match donor units to patients, reducing the risk of alloimmunization. They will also share examples of patient matching and advanced donor identification initiatives they have implemented.

Quotient will also be exhibiting at the Congress (booth no. C3.418).

New Solutions for the Global Transfusion Diagnostics Market
In January 2015, Quotient and Ortho announced an agreement to bring MosaiQ™, an innovative transfusion medicine diagnostic platform, to the market. The new technology promises to allow improved time to test results and more comprehensive matching of donor and patient blood, beyond what is available in current transfusion diagnostic instruments.

About Quotient Limited
Quotient is a commercial-stage diagnostics company committed to reducing healthcare costs and improving patient care through the provision of innovative tests within established markets. With an initial focus on blood grouping and donor disease screening (transfusion diagnostics), Quotient is developing its proprietary MosaiQ™ technology platform to disrupt and transform the $3.4 billion global transfusion diagnostics market. Quotient has over 30 years of experience developing, manufacturing and commercializing transfusion diagnostic products. The company's operations are based in Switzerland, Scotland and the US. For more information, visit: www.quotientbd.com .

About Ortho Clinical Diagnostics
Ortho Clinical Diagnostics is a global leader of in vitro diagnostics serving the clinical laboratory and immunohematology communities. Across hospitals, hospital networks, blood banks and labs in more than 120 countries, Ortho's high-quality products and services enable health care professionals to make better-informed treatment decisions. For the immunohematology community, Ortho's blood typing products help ensure every patient receives blood that is safe, the right type and the right unit. Ortho brings sophisticated testing technologies, automation, information management and interpretation tools to clinical laboratories around the world to help them run more efficiently and effectively and improve patient care. Ortho's purpose is to improve and save lives with diagnostics, and it does that by reimagining what's possible. This is what has defined Ortho for more than 75 years, and it's what drives Ortho forward. For more information, visit www.orthoclinicaldiagnostics.com .

Press Contacts:

Nicole Barraud-Estoppey
Quotient Ltd
nicole.barraud@quotientbd.com
+41 79 550 64 75

Renee Giello
Ortho Clinical Diagnostics
renee.giello@orthoclinicaldiagnostics.com
908-704-3678

Information om Marketwired

Marketwired
Marketwired
25 York Street, Suite 900, P.O. Box 403
M5J 2V5 Toronto, Ontario

416-362-0885http://www.marketwired.com/